There is a growing need to analyse multiple mutations associated with drug resistance because sequential or combinational use of antivirals is increasingly being used in treatment. In this study, we introduced a multiplex restriction fragment mass polymorphism (RFMP) assay for detecting mutations conferring entecavir and lamivudine resistance, and compared its performance with direct or clonal sequencing assays. Methods: Multiplex PCR was performed with mixed primers designed to interrogate rt184, rt202, rt204 and rt250. The PCR products were digested with restriction enzymes and the resulting fragments were analysed by mass spectrometry. A total of 251 serum samples, taken serially from 45 patients who received entecavir treatment after confirmed diagnosis of lamivudine resistance and inadequate adefovir dipivoxil response, were analysed by the multiplex RFMP assay. Results: The multiplex RFMP assay correctly identified known viral sequences with sufficient analytical sensitivity to detect as few as 100 IU/ml of HBV and with superior ability to determine haplotypes composed of neighbouring variations. Complex mutational patterns and relative abundances determined by multiplex RFMP assay were in good concordance with results obtained by direct or clonal sequencing analyses. Defined mixtures were successfully and consistently identified at 2% relative concentration of mutant versus wild-type virus by the assay. Conclusions: The multiplex RFMP assay is an accurate and sensitive means to detect entecavir and lamivudine resistance mutations, simultaneously. The method is expected to enable early and efficient diagnosis of multiple drug resistance mutations for optimal management of CHB.
Background: Drug resistance is a major limitation to the long-term efficacy of controlling chronic hepatitis B (CHB).
There is a growing need to analyse multiple mutations associated with drug resistance because sequential or combinational use of antivirals is increasingly being used in treatment. In this study, we introduced a multiplex restriction fragment mass polymorphism (RFMP) assay for detecting mutations conferring entecavir and lamivudine resistance, and compared its performance with direct or clonal sequencing assays. Methods: Multiplex PCR was performed with mixed primers designed to interrogate rt184, rt202, rt204 and rt250. The PCR products were digested with restriction enzymes and the resulting fragments were analysed by mass spectrometry. A total of 251 serum samples, taken serially from 45 patients who received entecavir treatment after confirmed diagnosis of lamivudine resistance and inadequate adefovir dipivoxil response, were analysed by the multiplex RFMP assay. Results: The multiplex RFMP assay correctly identified known viral sequences with sufficient analytical sensitivity to detect as few as 100 IU/ml of HBV and with superior ability to determine haplotypes composed of neighbouring variations. Complex mutational patterns and relative abundances determined by multiplex RFMP assay were in good concordance with results obtained by direct or clonal sequencing analyses. Defined mixtures were successfully and consistently identified at 2% relative concentration of mutant versus wild-type virus by the assay. Conclusions: The multiplex RFMP assay is an accurate and sensitive means to detect entecavir and lamivudine resistance mutations, simultaneously. The method is expected to enable early and efficient diagnosis of multiple drug resistance mutations for optimal management of CHB.
Chronic hepatitis B (CHB) is a leading cause of cirr hosis and hepatocellular carcinoma and, in addition to morbidity and mortality, results in significant social and economic burden [1, 2] . The level of HBV DNA is a crucial determinant of the progression to liver cirrhosis or hepatocellular carcinoma [3, 4] ; thus, effective sup pression of HBV DNA below the limit of detection of high sensitivity assays, without liver injury and devel opment of drug resistant mutations is a major aim of treatment [5] [6] [7] . Lamivudine (3TC) was the first approved nucleoside analogue for the treatment of CHB [8] ; however, the major limitation of 3TC is the development of drug resistant YMDD motif mutations in the HBV DNA polymerase [9] . A number of salvage agents add a new milestone in the treatment of 3TCresistant HBV infection [10, 11] . The encouraging results from clini cal studies of entecavir (ETV) have established it as the preferred firstline agent over the other available drugs, including 3TC, adefovir dipivoxil (ADV) and Introduction telbivudine [12] . Because the potency and resistance rates of ETV outweigh those of 3TC, similar or bet ter outcomes were expected with ETV treatment [13] ; however, recent studies have reported that patients in whom there had been previous resistance to 3TC have lower treatment responses and higher resistance rates to ETV. The persistence of 3TCresistant substitutions in patients who switched to ETV might lead to treat ment failure [14] . The high genetic barrier to ETV resistance is attributable to the requirement for three amino acid substitution mutations for resistance to occur, namely the 3TCresistant mutations rtM204 and rtL180, plus an additional mutation at codon rtT184, rt202 or rtM250 [13] . Previous studies suggest that the low binding affinity of ETV triphosphate for the HBV reverse transcriptase, involving conformational change of the binding pocket of HBV reverse transcriptase by rtL180M, rtM204V plus rtT184L, and rtS202G, could induce viral breakthrough [15] .
Monotherapy with sequential nucleoside/nucleotide analogues increases the risk of selection of multidrugre sistant HBV [11] . There is an increasing need to analyse several mutational hotspots associated with antiviral resistance simultaneously for optimal management of CHB [16] . It may be important to monitor not only the presence of mutations, but also the evolution of resist ance [17] . Sequencing has been widely used to search for known and unknown mutations; however, a major limi tation is the low sensitivity, which is generally reported as having a detection limit of 20% [18] [19] [20] .
The restriction fragment mass polymorphism (RFMP) assay is based on amplification and mass detec tion of oligonucleotides excised by typeIIS restriction enzyme digestion, using matrixassisted laser des orption/ionization timeofflight mass spectrometry (MALDI-TOF MS). The RFMP assay has been shown to be an accurate and reliable assay for clinical virus genotyping [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . In particular, the RFMP assay enables sensitive and quantitative detection of mix tures of viruses of multiple genotypes without the need for populationbased cloning and subsequent sequenc ing. RFMP could be a practical assay, in concert with regular measurements of the HBV viral load, for the early detection of 3TC resistance and timely introduc tion of new salvage agents [20] [21] [22] 27, 29, 30] .
In this study, we introduced an advanced MALDI-TOF MSbased assay that exploits the RFMP strategy and multiplex PCR for detecting commonly analysed 3TC and ETVresistant mutations. This procedure avoids repetitive PCR and mass spectrometric analy ses for multiple variations, simplifying and improving treatment monitoring. Its performance was compared with the singleplex RFMP assay and direct or clonal sequencing assays, and was found to be as accurate and as sensitive for genotyping drug resistant HBV.
Methods

Specimens
From 2006 to 2007, 45 CHB patients with prior 3TC resistance and inadequate ADV response were orally treated with 1.0 mg/day ETV alone at the Ajou Univer sity School of Medicine and the Yonsei University school of Medicine, Seoul, South Korea. All patients had HBV DNA levels ≥5 log 10 copies/ml before ETV administra tion. All patients had 3TC resistance characterized by virological breakthrough, which was defined as a con firmed increase in HBV DNA level of >1 log 10 copies/ ml compared with the nadir on therapy and selection of HBV variants with rt204 substitution, and had 3TC switched to ADV monotherapy. Inadequate virological response was defined as an HBV DNA level of >4 log 10 copies/ml at 24 weeks of treatment. Patients with inad equate ADV responses were switched to ETV mono therapy from ADV. A total of 15 (33%) patients had cirrhosis and 40 (89%) patients were positive for hepa titis B e antigen. The mean ±sd duration of ETV therapy was 13.4 ±3.0 months. Serial blood samples were taken before and every 3 months during therapy, and stored at 70°C until they were used for HBV molecular assay. All serum samples were determined to have genotype C by direct sequencing. HBV DNA was extracted from 200 µl of serum using the QIAamp blood kit (Qiagen, Chatworth, CA, USA) according to the manufacturer's instructions; 2 µl of the viral DNA was used for the PCR reaction. HBV DNA was determined quantitatively by a branched DNA assay (Versant 3.0; Bayer Healthcare LLC Diagnostic Division, Tarrytown, NY, USA), which has a detection limit of 2,000 copies/ml. A total of 251 HBVDNApositive blood samples were used for com paring the RFMP assay with sequencing. Experimental protocol followed the ethical guidelines of the 1975 Declaration of Helsinki, as reflected in a priori approval by participating institutional review boards.
Multiplex RFMP assay
PCR reaction was performed in 25 µl of reaction mixture containing 20 mM TrisHCl (pH 8.4), 50 mM KCl, 0.2 mM dNTP, 400 nM of primers and 0.4 units of Platinum ® Taq DNA polymerase (Invitrogen, Calsbad, CA, USA). The initial denaturing phase of 5 min at 94°C was followed by a 45cycle amplifica tion phase containing a denaturation step at 94°C for 15 s, an annealing step at 55°C for 15 s and an elon gation step at 72°C for 15 s. Amplification was termi nated by incubation at 72°C for 5 min. For multiplex analysis of codon rt184, rt202, rt204 and rt250, mixed pools of primers including 184mf, 202mr, 204mf and 250mr were used. For confirmatory singleplex analysis of codon rt184, rt202, rt204 and rt250, primer pairs such as 184mf/184sr, 202sf/202mr, 204mf/204sr and 250sf/250mr were used, respectively. Nucleotide (nt) sequence positions were numbered according to Ono et al. [31] . The primer sequences were as follows: 5′CCTCAGTCCGTTTCTCCTCTGAAGCCGGC TCAGTTT3′ (nt 651-676) for 184mf, 5′TTGGCC CCCAATACCACACTGAAGtCCGGTCCATA TA3′ (nt 736-764) for 202mr, 5′TTTCCCCCACT GTTTGGCTGAAGttCCGGAGTTAT3′ (nt 711-738) for 204mf, 5′AAAGTACCCCAACTTCCA CTGAAGtttCCGGATATCC3′ (nt 880-908) for 250mr, 5′TTGGCCCCCAATACCACATCCATA TA3′ (nt 736-764) for 184sr, 5′CCTCAGTCC GTTTCTCCTCTCAGTTT3′ (nt 651-676) for 202sf, 5′AAAGTACCCCAACTTCCAATATCC3′ (nt 880-908) for 204sr and 5′TTTCCCCCACTGTTTGGAGTTAT3′ (nt 711-738) for 250sf. The sequence underlined in each primer was introduced to generate new AcuI or MspI sites in the PCR products. Restriction enzyme digestion of PCR products was performed by mixing the PCR reaction mixture with 10 µl of buffer containing 50 mM potas sium acetate, 20 mM Trisacetate, 10 mM magnesium acetate, 1 mM dithiothreitol, 60 µM Sadenosylmethio nine and 1 unit of AcuI enzyme. The reaction mixture was incubated at 37°C for 1.5 h and further incubated at the same temperature for 1.5 h with MspI. Desalting of resulting digest and mass analysis were performed as described previously [22] .
Direct and clonal sequencing analyses
To amplify the HBV polymerase gene encoding the rt184, rt202, rt204 and rt250 for clonal and direct sequencing, PCR was performed with the primer pair HBV clonef (5′CTCACCAACCTCTTGTCCTC3′, nt 334-353)/ HBV cloner (5′AAAGTACCCCAACTTCCAAT3′, nt 889-904). The PCR products were cloned into the pCRScript Amp cloning vector (Stratagene, La Jolla, CA, USA) and subsequently sequenced with vector specific primers. Approximately 100 clones per serum were randomly selected for clonal sequencing analysis. Direct PCR products or cloned DNAs were sequenced with the BigDye Terminator v3.1 Cycle Sequencing kit and ABI PRISM 310 Analyzer (Applied Biosystems, Foster City, CA, USA).
Results
Multiplex RFMP assay strategy
The RFMP assay is based on mass spectrometric analysis of small DNA fragments, including sites of mutation [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . A multiplex RFMP assay was designed as illustrated in Additional file 1. The for ward and reverse primers were designed to intro duce two enzyme sites, AcuI (CTGAGG) and MspI (CCGG), in the amplified product. Linker bases were added to restriction core sequences between the AcuI and MspI site in primers addressing rt202, rt204 and rt250, to give the size difference in restriction frag ments. As summarized in Table 1 , the released diag nostic fragments from enzymatic digestion consist of unique sizes such as 11mer/15mer for rt184 codon, 10mer/14mer for rt202, 9mer/13mer for rt204 and 8mer/12mer for rt250, leading to easy identification of sequence variation in multiple codons in a single mass spectrum.
Genotype analysis of mutations at rt184, rt202, rt204 and rt250, as assessed by single and multiplex RFMP assays, were in full agreement for a total of 251 serum samples. Singleplex RFMP results showed two distinct peaks relevant to each target, whereas multi plex RFMP showed eight distinct mass peaks for the four mutations, with the mass values of each diagnostic fragment in the multiplex assay being exactly the same as those in the singleplex RFMP ( Figure 1 and Table 1 ). Viral ratios observed in mixed infections with wildtype and mutant virus populations for rtT184L were identi cal between both assays ( Figure 1 ).
Analytical sensitivity and detection of the mixed genotype population
Analytical sensitivity of the multiplex RFMP assay was estimated to be 300 copies/ml, and is similar to those obtained by singleplex RFMP for in the detection of 3TC or ADV resistanceassociated mutant strains [25] . To compare the ability to detect minor mutant virus in mixed populations, the samples constituted of defined ratios of mutant and wildtype DNA of each codon were analysed by multiplex RFMP assay. We cloned each ref erence plasmid for rt184T/S, rt202S/G, rt204M/I/V and rt250M/l out of PCR products spanning nt 316-904 of the HBV genome from patient serum. Defined mixtures were made with the following percentages of mutant virus over the total virus population: 100%, 50%, 20%, 2% and 0.5%. The mutant type of rt184 and rt202 could be detected in up to 2% of the total virus population (Additional file 2). The same limit of detec tion was observed in rt204 and rt250 codons (KHH et al., data not shown).
Comparison of multiplex RFMP with direct and clonal sequencing analyses
Of 251 HBVpositive sera taken consecutively from 45 patients, the RFMP assay detected mutant virus with at least one of the rt184, rt202 and rt204 codons in 80.4% (202/251) of the sera (Table 2) . Mutant virus with the rt184, rt202 and rt250 mutations were detected in 21 (8.4%) of the sera, all with the rt204V/I mutation. Using direct sequencing, identical results were found with 215 (85.6%) specimens; however, in 36 (14.3%) samples, the results differed from those obtained by multiplex RFMP. Direct sequencing could not identify specific genotypes with a double mutation in one codon (Table 2 ). This is a result of the inability of sequencing to determine the correct variant present in the sample when nucleotide mixture at position 1 (A or G) and position 3 (T or G) of codon 204 are present. As shown in Table 2 and Figure 2A , rt204V/I mixtures detected by the multiplex RFMP could be scored as rt204V (GTT) plus rt204M (ATG), rt204V (GTG) plus rt204I (ATT) or rt204V (GTG) plus rt204I (ATT) plus rt204M (ATG) by direct sequencing in 31 of 251 (12.3%) sera. Equally, five samples showed double mutations com posed of nucleotide mixtures at position 1 (A or C) and position 2 (C or T) of codon 184 in direct sequencing analysis, which could be interpreted as rt184T (ACT) plus rt184L (CTT) or rt184T (ACT) plus rt184L (CTT) plus rt184I (ATT), although rt184P (CCT) has never been reported and its presence is excluded, whereas multiplex RFMP unambiguously determined rt184T wildtype along with the rt184L mutant ( Table 2 and Figure 2B ). One nucleotide mixture at a single position, such as A or G at position 1 at codon 204, G or A at position 1 at codon 202 and A or C at position 1 at codon 250, were correctly scored as Val plus Ile, Gly plus Ser and Met plus Leu mixtures, respectively, at cor responding codons by sequence analysis (Table 2 and Figure 2C and 2D).
The combined genotypes at multiple codons and mixture infections shown in the multiplex RFMP were further confirmed by the clonal sequencing. PCR prod ucts spanning the reverse transcriptase domain of HBV reverse polymerase were cloned, and approximately 100 clones per serum sample were analysed and com pared with multiplex RFMP. Overall, the multiplex RFMP assay was in excellent agreement with clonal sequencing (Table 3) . Patients 2, 9 and 13 were found to have rt184T wildtype and rt184L mutant in ratios of 10:1, 1:5 and 1:6, respectively. In parallel, clonal sequencing analysis exhibited almost the same ratios of genotypes as assessed by the number of clones contain ing each genotype (9.2:1, 1:5.5 and 1:5.6). Similarly, multiplex RFMP and clonal sequencing were in good agreement in codon rt202 (patients 2 and 13), in codon 204 (patients 10, 11 and 12) and in codon 250 (patient 2), in terms of the detection of minor species and rela tive abundance of virus (Table 3) .
Treatment responses in relation to the evolution of 3TC and ETV resistance-associated mutants
In order to study the evolution of relevant ETV resistant mutations during ETV treatment, we performed longi tudinal analyses of six participants who developed ETV resistant mutations. The treatment response in relation to the presence of ETVresistant (rtT184SCGA/ILFM, rtS202G/I, rtI169T and rtM250V) and 3TC resistant (rtL180M and rtM204V) mutations are shown in Fig  ure 3 . Patient 1 exhibited the rtS202G mutation tran siently without any additional ETVresistant mutations. Although ETV therapy led to a temporary disappear ance of this mutation, viral load was not increased. In the cases of patients 2, 9, 13 and 16, who exhib ited the rtT184L mutation, viral load was increased in proportion to the increase of rt184L and/or rt202G mutant viral populations, as measured by the mutant specific mass peak area in MALDITOF MS spectra. Patient 2, who had a transient rtT184L mutation, exhibited a decrease in viral load. In contrast to the case of patient 2, increased viral load was observed in patient 9, who exhibited increased rt184L mutant virus relative to the wildtype populations. In patient 16, dis appearance of the rtT184L mutation and emergence of the rtS202G mutation was observed at 48 weeks of ETV therapy. At this time point, increased viral load was observed in patient 16. Among previously reported rtT184SCGA/ILFM substitutions, the rtT184L muta tion was the most frequent and rtT184S/C was detected in a single patient. The initially observed rtT184S/C persisted throughout ETV treatment (patient 41). No rtS202I or rtT184GAIFM substitutions were detected in our cohort.
Discussion
Multidrug resistance to nucleoside/nucleotide analogues is increasing concomitantly with HBV variants with com plex mutational patterns; therefore, there is a need for simultaneous analysis of the mutations associated with antiviral resistance for optimal management of CHB [19, 30] . The performance of the RFMP assay for detect ing 3TC and ADVresistant mutations has been widely evaluated in many studies [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] , and has been found to be an accurate and reliable method for early detec tion of 3TCresistant mutations and to be more sensi tive than hybridizationbased assays [20] [21] [22] 27, 29, 30] . The RFMP assay is useful for the detection of slight genetic variants at viral loads as low as approximately 100 IU/ ml [29] .
In the present study, we established an advanced multiplex RFMP assay to exploit differential lengths of oligonucleotides (9-15mer) depending upon mul tiple target codons that are associated with 3TC and ETVresistant mutations, including rt184, rt202, rt204 and rt250, which does not necessitate repetitive PCR and multiple mass spectrometric analyses. Our results, from a panel of 45 CHB patients evaluated in paral lel by singleplex RFMP assay and sequence analysis, showed that multiplex RFMP is a reliable method for detection of ETV and 3TCresistant mutations. The multiplex RFMP assay reproducibly and successfully identified the genotypes at four codons in all the tested clinical samples, and mutational patterns obtained by multiplex assay showed 100% concordance with those obtained by repetitive analysis of each singleplex RFMP and clonal sequencing ( Figure 1 and Table 3 ). The mul tiplex RFMP assay exhibited analytical sensitivity and a lower limit of detection for minority mutant popula tions as low as 300 copies/ml and 2% of any of four codons associated with ETV resistance.
The performance of the multiplex RFMP assay for detecting mutations related to ETV resistance was compared with direct sequencing for 251 samples of 45 CHB patients who experienced 3TC resistance, inadequate ADV response and switched to ADV then ETV sequential monotherapy: 85.6% of the samples showed similar results, whereas 14.3% showed differ ent results, where direct sequencing could not identify specific genotypes with double mutations in one codon. These findings are explained by the inability of sequence assays to determine variants in mixtures at position 1 and position 3 of codon 204 or at position 1 and posi tion 2 of codon 184 (Table 2 and Figure 2) .
The RFMP assay detected mutant viruses with rt169, rt184, rt202 and rt250 codons in 0% (0/251), 5.5% (14/251), 3.2% (8/251) and 0.4% (1/251) of the sera, respectively, at 48 weeks of ETV therapy (Table 2) . Based on multiplex RFMP, rtT184S/C/I/L and rtS202G substitutions were detected in 15% of the sera during 48 weeks of ETV therapy. The prevalences of rt184 and rt202 ETVresistant substitutions in our cohort were higher than those reported in previous studies, based on assessment of ETV treatment at week 48 using direct sequencing wherein ETVresistant mutations emerged in 6% of 3TC refrectory patients. In our cohort, neither the rtS202I nor the rtT184GAIFM substitution was detected and rtT184L substitutions were most frequent among previously reported various rtT184SCGA/ILFM substitution types.
Previous clinical studies and structural data suggest that ETVresistant (rtT184SCGA/ILFM and rtS202G, but not rtS202C), in addition to 3TCresistant (rtL180M and rtM204V), mutations can induce viral breakthrough during ETV therapy [13] ; however, the combination of ETV and 3TCresistant mutations that is important for viral breakthrough during ETV treatment is unknown. This study investigated treatment responses in relation to the presence of ETVresistant (rt184, rt202, rt169 and rt250) and 3TCresistant (rt180 and rt204) muta tions, and relative abundance of wild and mutant types. Patient 1 exhibited the rtS202G mutation without any additional ETVresistant mutations. Although the ETV therapy in patient 1 led to a temporary disappearance of this mutation, viral rebound was not observed. The The known entecavir (ETV) and lamivudine (3TC) resistance mutations at rt169, rt180, rt184, rt202, rt204 and rt250 were analysed by singleplex and/or multiplex restriction fragment mass polymorphism (RFMP) genotyping at baseline and every 3 months during ETV administration. HBV DNA was measured using a branched DNA assay with a cutoff of 3.3 log 10 copies/ml. ND, not detectable.
existence of an rt202G mutant population without additional rt184 substitution did not exacerbate the ETV therapy. In contrast to the patient with rt202G, the patients with the rtT184L mutation during ETV therapy showed viral load change in proportion to the rise in the ratio of rt184L mutant population to wild type population (patients 2, 9 and 13). Whereas patient 2 with a transient rtT184L mutation showed a decrease in viral load, patient 9 showed an increase in the amount of rt184L mutant relative to the wildtype populations (that is, from a wildtype:mutant ratio of 5:1 to 1:5); shortly thereafter, an increasing level of viral load was observed in patient 9 at 60 weeks. In contrast to the rt202G predominance, rt184L mutant predominance exacerbated the ETV therapy. It is of interest that, in patient 41, the initially observed rtT184S/C, which is a relatively rare substitution among rt184 substitutions, persisted throughout ETV treatment, although this patient never achieved HBV DNA level <6 log 10 copies/ ml during ETV administration ( Figure 3 ). These observations suggest that evolution of rtT184L is most strongly associated with virological response to ETV among rtT184SCGA/ILFM and rtS202G/I/C, rtI169T and rtM250V mutations. The evolution of rtS202G, but not rtS202C is also associated with viro logical response. Our work raises the question of how patients with an evolving rt184L mutant population should be treated. One could argue that ETV treatment should be stopped in order to reduce the selection pres sure for the mutant population. By contrast, ETV ther apy retards CHB progression by elimination of unmu tated viral population. In the latter case, a combination of additional drugs could be beneficial. To assess the prognostic significance of rt184L mutant evolution, the additional role of rt202G mutants in ETV resistance needs to be further investigated.
Resistance should be identified as early as possible before clinical breakthrough by means of sensitive HBV DNA monitoring. In addition to the sensitive detection of viral load, sensitive and accurate identification of the drug resistant genotype is desirable for early treat ment intervention. Current methods of characterizing HBV drugresistant mutations include direct sequenc ing, clonal sequencing and hybridizationbased assays. Direct sequencing detects mutations present in >20% of the circulating mixture populations, but does not allow easy estimation of ratios between multiple virus mixtures. The sequencing of multiple virus clones has higher sensitivity for detecting minute amounts of mutant virus, but it is labour intensive and not feasible for routine diagnosis in a clinical setting. The reverse hybridizationbased assay has a higher sensitivity than direct sequencing, but it is subject to falsepositive and negative results more frequently than is sequencing. The multiplex RFMP assay is highly sensitive to detect as low as 2% of drug resistant mutant virus in total virus populations and advantageous in assessing geno type dynamics of viral quasispecies as it can determine relative abundance semiquantitatively. The expanded perspective on emerging drug resistant mutant viruses and the evolution of mutations by multiplex RFMP can provide a valuable insight into the understanding of how resistance develops and enables early strategic decisions of antiviral treatment in the management of CHB.
